Delafloxacin

Summary

Delafloxacin (CHEMBL2105637) is an approved small molecule (ATC J01MA23); indicated across 6 conditions including bacterial infectious disease and gonorrhea.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01MA23
• Indications: 6 conditions
• Clinical trials: 13
• Chemistry: 440.8 Da · C18H12ClF3N4O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105637
Name	Delafloxacin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	487101
ATC	J01MA23
Molecular formula	C18H12ClF3N4O4
Molecular weight	440.8
InChIKey	DYDCPNMLZGFQTM-UHFFFAOYSA-N

SMILES: C1C(CN1C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4=C(C=C(C(=N4)N)F)F)F)O

IUPAC name: 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid

Also known as: ABT-492, Delafloxacin, Delafloxacine, Delafloxacino, RX-3341, WQ-3034, DELAFLOXACIN, delafloxacin

Parent form; salt/anhydrous children: CHEMBL2105638

Patent coverage: 327 distinct patent families (790 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 630 (80%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
gonorrhea	3	MONDO:0004277	DOID:7551
bacterial pneumonia	3	MONDO:0004652	EFO:1001272
liver disorder	1	MONDO:0005154	EFO:0001421
pneumonia	1	MONDO:0005249	EFO:0003106

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
PHASE3	5
PHASE1	4
PHASE2	2
PHASE4	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05977868	PHASE4	TERMINATED	Comparing Oral Versus Parenteral Antimicrobial Therapy
NCT01811732	PHASE3	COMPLETED	Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
NCT01984684	PHASE3	COMPLETED	Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
NCT02015637	PHASE3	TERMINATED	Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea
NCT02679573	PHASE3	COMPLETED	Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia
NCT04042077	PHASE3	TERMINATED	Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections
NCT00719810	PHASE2	COMPLETED	Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections
NCT01283581	PHASE2	COMPLETED	A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
NCT02245243	PHASE1	COMPLETED	Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment
NCT02505997	PHASE1	COMPLETED	Study to Evaluate the Effect of Delafloxacin on the Pharmacokinetics of Midazolam in Healthy Subjects
NCT03534622	PHASE1	COMPLETED	Evaluate Safety and Pharmacokinetic To Assess Bronchopulmonary Disposition of Intravenous Delafloxacin in Healthy Adults
NCT06612255	PHASE1	TERMINATED	A Study Comparing the Bioavailability of a Taste-masked Delafloxacin Powder for Oral Suspension With the Delafloxacin Tablet in Healthy Adults
NCT07426471	Not specified	NOT_YET_RECRUITING	Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).